The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Δημοσίευση

Lung inflammatory response syndrome after cardiac-operations and treatment of lornoxicam.

TitleLung inflammatory response syndrome after cardiac-operations and treatment of lornoxicam.
Publication TypeJournal Article
Year of Publication2014
AuthorsTsakiridis, K., Mpakas A., Kesisis G., Arikas S., Argyriou M., Siminelakis S., Zarogoulidis P., Katsikogiannis N., Kougioumtzi I., Tsiouda T., Sarika E., Katamoutou I., & Zarogoulidis K.
JournalJ Thorac Dis
Volume6 Suppl 1
PaginationS78-98
Date Published2014 Mar
ISSN2072-1439
Abstract

The majority of patients survive after extracorporeal circulation without any clinically apparent deleterious effects. However, disturbances exist in various degrees sometimes, which indicate the harmful effects of cardiopulmonary bypass (CPB) in the body. Several factors during extracorporeal circulation either mechanical dependent (exposure of blood to non-biological area) or mechanical independent (surgical wounds, ischemia and reperfusion, alteration in body temperature, release of endotoxins) have been shown to trigger the inflammatory reaction of the body. The complement activation, the release of cytokines, the leukocyte activation and accumulation as well as the production of several "mediators" such as oxygen free radicals, metabolites of arachidonic acid, platelet activating factors (PAF), nitric acid, and endothelin. The investigation continues today on the three metabolites of lornoxicam (the hydroxylated metabolite and two other metabolites of unknown chemical composition) to search for potential new pharmacological properties and activities.

DOI10.3978/j.issn.2072-1439.2013.12.07
Alternate JournalJ Thorac Dis
PubMed ID24672703
PubMed Central IDPMC3966166

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.